The Published Trial Record: Phase 1 Through Phase 3

Start here: what Retatrutide research has established so far

Retatrutide is a synthetic peptide that activates three hormone receptors at once — GIP, GLP-1, and glucagon. It is investigational: not approved, studied under clinical-trial conditions only. The research record runs from a Phase 1b pharmacokinetics study in 2022 through a Phase 3 trial in type 2 diabetes reported in 2026, with an ongoing Phase 3 obesity and outcomes program.

Here is what the trials have measured: retatrutide produces large weight losses, significant blood-sugar reductions in diabetes, and dramatic liver-fat clearance in fatty liver disease. The mechanism behind all three outcomes is the same triple-receptor approach — GLP-1 and GIP handle glucose and appetite; glucagon adds energy burning. The Phase 3 data are still accumulating. Long-term cardiovascular and kidney outcomes are the open questions the current trials are designed to answer.

Everything below is sourced to the peer-reviewed literature. The full citation list is on Retatrutide references.

Structural pharmacology: how the molecule binds

Cryo-EM structures resolved retatrutide simultaneously engaging GLP-1R, GIPR, and GCGR — the first structural confirmation of triple agonism at atomic resolution ^[3]. Relative potency versus native endogenous hormones: 8.9× at GIPR (superagonist), 0.3× at GCGR, 0.4× at GLP-1R. The extracellular loop 1 (ECL1) adopts a rigid alpha-helix in GLP-1R and GCGR but a flexible loop in GIPR — explaining the differential receptor engagement that makes retatrutide distinct from native GIP or GLP-1.

The molecule is a 39-amino-acid peptide built on a GIP-based backbone, acylated with a C20 fatty diacid for albumin binding and extended plasma half-life. Molecular weight: 4731.33 Da; formula C221H342N46O68. The half-life of approximately 6 days, measured in Phase 1b PK studies ^[4], supports the once-weekly dosing schedule used across all trials.

A 2026 mechanistic review characterized retatrutide's triple agonism as mimicking the pleiotropic nutrient-stimulated hormonal responses seen after bariatric surgery, with broad clinical utility across hepatic, cardiovascular, and metabolic domains — a paradigm shift from glucose-lowering alone ^[10].

Phase 1b: first-in-human pharmacokinetics and early efficacy (2022)

The first-in-human Phase 1b trial enrolled 72 adults with type 2 diabetes (HbA1c 7.0–10.5%) in a multiple-ascending-dose design over 12 weeks ^[4]. Dose groups: 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg once weekly subcutaneous.

Key PK finding: half-life approximately 6 days, consistent across dose groups, confirming the weekly dosing hypothesis. Placebo-adjusted weight loss at the highest-dose group: -8.96 kg (90% CI -11.16 to -6.75). Daily glucose reduction: -2.8 mmol/L at 3 mg. Treatment-emergent adverse events in 63% of participants, predominantly GI, mostly mild. The safety profile was characterized as acceptable — no serious adverse events related to the compound.

This trial established the PK foundation for the Phase 2 program's dose-range selection.

Phase 2 obesity trial: 48 weeks, n=338 (2023)

The pivotal Phase 2 obesity trial (published in the New England Journal of Medicine, 2023) enrolled 338 adults with obesity or overweight with at least one comorbidity, over 48 weeks ^[1]. Doses: 1, 4, 8, or 12 mg once weekly subcutaneous.

Primary endpoint — weight change:

• 12 mg: -24.2% mean body weight vs -2.1% placebo
• 8 mg: -17.3%
• 4 mg: -8.7%
• 1 mg: -3.7%

At 12 mg, 26% of participants achieved ≥30% body weight loss. Adverse events: GI effects (nausea, diarrhea, vomiting) were dose-related and mostly mild to moderate. Dose-dependent heart rate increase peaking at week 24, mean 5–7 bpm at highest doses. Discontinuation due to adverse events: 18% at 12 mg.

A review published in Biomolecules (2025) characterized the 24% weight loss as a step-change versus prior incretin therapies, representing the first Phase 2 data approaching bariatric-surgery-level outcomes ^[6].

Phase 2 type 2 diabetes trial: 36 weeks, n=281 (2023)

A randomized double-blind Phase 2 trial in adults with type 2 diabetes and inadequate glycemic control on diet and exercise enrolled 281 participants across 0.5–12 mg stepwise escalation ^[2]. Published in The Lancet, 2023.

Primary endpoints at 24 weeks (HbA1c):

• 12 mg: -2.02% HbA1c vs -0.01% placebo
• 8 mg: -1.83%

Secondary endpoints at 36 weeks (weight):

• 12 mg: -16.94% body weight vs -3.00% placebo

No severe hypoglycemia in participants not on background insulin. Mild-to-moderate GI adverse events in 35% of participants. No deaths. The trial established glycemic and weight efficacy across a broad escalation range and confirmed the GI safety profile documented in Phase 1b.

Phase 2 MASLD substudy: liver fat, 48 weeks, n=98 (2024)

A Phase 2a substudy enrolled 98 participants with obesity or overweight and MASLD (metabolic dysfunction-associated steatotic liver disease) — defined as ≥10% liver fat by MRI-PDFF (magnetic resonance imaging proton density fat fraction), without type 2 diabetes ^[5]. Published in Nature Medicine, 2024.

Liver fat change at 24 weeks (relative):

• 12 mg: -82.4% relative reduction vs +0.3% placebo
• 8 mg: -81.4%
• 4 mg: -57.0%
• 1 mg: -42.9%

At 12 mg, 86% of participants reached normal liver fat (<5%) at 24 weeks. Reductions sustained to 48 weeks (-86.0% at 12 mg). This was published in the same year as emerging data on GLP-1-class therapies for MASH (metabolic-associated steatohepatitis) resolution ^[9], placing retatrutide in context as one of the most potent liver-fat-clearing compounds in the investigational pipeline.

Phase 3 TRANSCEND-T2D-1 readout (2026)

The first Phase 3 data published from the retatrutide program was TRANSCEND-T2D-1 (n=537 adults with type 2 diabetes), a 40-week randomized double-blind placebo-controlled trial ^[12]. Published in The Lancet, 2026.

Results at 40 weeks:

• Retatrutide 12 mg: HbA1c -1.94% vs -0.81% placebo; body weight -15.3% vs -2.6% placebo
• Treatment discontinuation due to adverse events: 8.5% at 12 mg vs 2.2% placebo
• No severe hypoglycemia
• Adverse events: predominantly mild-to-moderate GI

These results confirm Phase 2 findings at Phase 3 scale in a diabetes population and represent the first regulatory-grade trial data for retatrutide. The TRIUMPH obesity program and cardiovascular/kidney outcomes trials remain ongoing.

Retatrutide vs tirzepatide

Tirzepatide is a dual GIP/GLP-1 agonist that is approved for type 2 diabetes and obesity. Retatrutide adds glucagon receptor agonism to that dual foundation, creating the triple-agonist profile. In Phase 2 data, retatrutide 12 mg/48 weeks produced -24.2% body weight loss — higher than tirzepatide's Phase 3 peak of approximately -20–22% at the highest approved dose.

Retatrutide has progressed to Phase 3 with an active-comparator arm versus tirzepatide in the TRIUMPH program, which will provide the first randomized head-to-head data ^[8]. Until that reports, the cross-trial comparison is hypothesis-generating, not definitive — study populations, escalation schedules, and trial durations differ.

A 2026 review concluded that retatrutide achieves weight reduction currently unmatched in the oral/injectable pipeline, but that the class-level limitation — weight regain upon discontinuation — applies here as well ^[14]. The glucagon arm adds energy expenditure, but whether it changes the long-term metabolic set point is unknown.

Is retatrutide fda approved

No. Retatrutide is not FDA-approved and not approved by any regulatory agency as of mid-2026. It is an investigational compound in Phase 3 clinical trials. The TRIUMPH-1/2 obesity trials and the TRANSCEND series in type 2 diabetes are ongoing. An NDA (New Drug Application) has not been submitted to the FDA. A regulatory timeline has not been publicly confirmed by Eli Lilly as of the current date.

No retatrutide product can be legally prescribed or purchased as a medication in the United States or elsewhere.

Retatrutide availability

Retatrutide is not available by prescription. It is accessible only through participation in clinical trials. Outside of trials, gray-market research-labeled material circulates in unregulated channels, but such material carries unverified identity, purity, and sterility risks — it cannot be confirmed to be authentic retatrutide.

Clinical trial enrollment can be explored at ClinicalTrials.gov by searching NCT numbers in the TRIUMPH and TRANSCEND programs.

When will retatrutide be available

No approval date has been confirmed. Phase 3 trials are ongoing as of 2026. Regulatory submission would follow Phase 3 completion and data analysis — a process that typically takes additional years after the last trial reports. Estimates circulating in media are speculative. This site will not publish timeline projections unsupported by official filings.